Newsroom

April 19, 2016

Constellation Pharmaceuticals, Inc. To Present At The Epigenetics: Cancer and Beyond Symposium

CAMBRIDGE, Massachusetts, April 20, 2016 – Constellation Pharmaceuticals, Inc., a leader in the rapidly expanding field of epigenetics, today announced that Patrick Trojer, PhD, Vice President of Research, will present at the Epigenetics: Cancer and Beyond Symposium on Thursday, April 28, 2016, starting at 9:00 a.m.…

Read more »


April 4, 2016

Constellation Pharmaceuticals, Inc. To Present At The 15th Annual Needham Healthcare Conference

CAMBRIDGE, Massachusetts, April 4, 2016 – Constellation Pharmaceuticals, Inc., a leader in the rapidly expanding field of epigenetics, today announced that Keith Dionne, PhD, President and Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016, at 2:00 p.m.…

Read more »


January 5, 2016

Constellation’s CEO Keith Dionne to present at 34th Annual J.P. Morgan Healthcare Conference in San Francisco. 7:30 am on January 11th 2016

CAMBRIDGE, January 5, 2016.  Constellation’s CEO, Keith Dionne, will be presenting a corporate update at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2016 at 7:30 a.m. Pacific at the Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session.…

Read more »


December 9, 2015

Constellation Pharmaceuticals, Inc. Raises $55 Million in Mezzanine Financing

Funding Supports Advancement of Pipeline and Epigenetics Platform CAMBRIDGE, Massachusetts, December 9, 2015 – Constellation Pharmaceuticals, Inc., a leader in the rapidly expanding field of epigenetics, today announced the successful completion of a $55 million mezzanine round of financing. The Company plans to use the proceeds from the financing to advance its pipeline of direct tumor targeting and immuno-stimulatory epigenetic inhibitors, which includes its two wholly-owned, clinical-stage lead programs: a bromodomain and extra-terminal (BET) inhibitor as well as an EZH2 inhibitor, targeting difficult-to-treat cancers.…

Read more »


December 9, 2015

Constellation Pharmaceuticals, Inc. Raises $55 Million in Mezzanine Financing

Funding Supports Advancement of Pipeline and Epigenetics Platform CAMBRIDGE, Massachusetts, December 9, 2015 – Constellation Pharmaceuticals, Inc., a leader in the rapidly expanding field of epigenetics, today announced the successful completion of a $55 million mezzanine round of financing. The Company plans to use the proceeds from the financing to advance its pipeline of direct tumor targeting and immuno-stimulatory epigenetic inhibitors, which includes its two wholly-owned, clinical-stage lead programs: a bromodomain and extra-terminal (BET) inhibitor as well as an EZH2 inhibitor, targeting difficult-to-treat cancers.…

Read more »


April 28, 2015

Constellation Pharmaceuticals Initiates Clinical Development of CPI-1205, a Novel Inhibitor of EZH2, in Patients with Lymphoma

Second Constellation Pipeline Program to Enter the Clinic CAMBRIDGE, Mass. –April 28, 2015 – Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of chromatin biology, today announced that it has initiated a Phase 1 clinical trial of CPI-1205, a novel inhibitor of EZH2, in patients with previously treated and progressive lymphomas.…

Read more »


October 9, 2014

Constellation meets contractual milestones and receives balance of $15 million loan

Today, Constellation announced that it has secured a $15 million senior secured loan with Oxford Finance and Silicon Valley Bank.  Constellation had already drawn down $5 million from this facility, which was originally closed back in June of 2013 and, having met contractual milestones, the company received the balance of the loan this month. …

Read more »


October 9, 2014

Constellation meets contractual milestones and receives balance of $15 million loan

Today, Constellation announced that it has secured a $15 million senior secured loan with Oxford Finance and Silicon Valley Bank.  Constellation had already drawn down $5 million from this facility, which was originally closed back in June of 2013 and, having met contractual milestones, the company received the balance of the loan this month. …

Read more »


August 4, 2014

Constellation Expands Clinical Studies of CPI-0610

Today, Constellation announced that it has initiated two additional clinical studies of its lead BET Inhibitor, CPI-0610.  CPI-0610 has been progressing in a Phase 1 clinical trial in patients with lymphoma since September of 2013.  As that trial continues, two new Phase 1 clinical trials of CPI-0610 were started in July of this year.…

Read more »


April 2, 2014

Constellation Pharmaceuticals will give a presentation on EZH2 and exhibit posters on EZH2 and BET at the AACR Annual Meeting, April 5-9 in San Diego, CA.

At this year’s AACR Annual Meeting Constellation will be represented by one oral presentation and four posters encompassing work on chromatin biology. Patrick Trojer will be giving a talk entitled “Targeting Histone Lysine Methylation in Cancer”, in Saturday's 11:45 am session, room 28 A-C.…

Read more »


Connect With Us

For inquiries or to request additional information we can be reached via:

Online Form Phone (617) 714-0555 Full Contact Info